Table D-7. Evidence table for studies addressing management of PPH (Mallaiah 2014)

| **Study** **Description** | **Intervention** | **Inclusion/Exclusion** **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| **Author:**Mallaiah et al., 20148**Country:**UK**Enrollment period:** April 2011 toJune 2013**Birth setting:** Hospital**Facility characteristics:** Tertiary care, **Funding:** NR**Design:** Pre-post | **Intervention:** Phase 1- shock pack major hemorrhage packs of 4 units RBS, 4 units FFP, and one adult dose of plateletsPhase 2- fibrinogen- protocol updated to remove blind administration of FFP from start of pathway**Groups:****G1:** shock pack April 2011-Mar 2012**G2:** fibrinogen July 2012 to June 2013**N at enrollment:** **G1:** 42**G2:** 51**N at follow-up:** **G1:** 42**G2:** 51**Duration of treatment:** NR**Timing of treatment:** NR**Order of treatment:** NR**Length of follow-up:** NR | **Operational definition of PPH:** Estimated blood loss > 1500 mL**Definition of success of treatment**: NR**Method of blood loss measurement:** NR**Severity:** NR**Inclusion criteria:** Major obstetric hemorrhage, EBL > 1500 mL) associated with coagulopathy (FIBTEM A5 < 12 mm, indicative of plasma fibrinogen level of 2 g.l-1**Exclusion criteria:** patients receiving anticoagulant therapy**Maternal age, yrs, mean ± SD:** NR**Parity, n:** NR**Weeks gestation, n (%):** NR**Single pregnancy, n (%):** NR**Multiple pregnancy, n (%):** NR**Race/ethnicity:** NR**BMI:** NR**Baseline hemoglobin:** NR**SES:** NR**Mode of birth, n:** NR**Risk factors, n (%):** NR**Primary etiology of PPH, n:** Abruption**G1:** 3**G2:** 7Placenta previa**G1:** 5**G2:** 1Trauma**G1:** 11**G2:** 19Atony**G1:** 7**G2:** 5Uterine inversion**G1:** 0**G2:** 2Other**G1:** 6**G2:** 17 | **Blood loss, n:**< 1499 mL**G1:** 10**G2:** 121500-2999 mL**G1:** 12**G2:** 193000-4999 mL**G1:** 8**G2:** 7> 5000 mL**G1:** 3**G2:** 3Not recorded**G1:** 9**G2:** 10**Transfusion, median (range):** Blood components**G1:** 8.0 (0-32)**G2:** 3.0 (0-26p= 0.0004Fibrinogen**G1:** 3.2 (0-20.4)**G2:** 0 (0-12.4)p= 0.0005**ICU admission, n (%)****G1:** 4 (9%)**G2:** 1 (2%)**Anemia:** NR **Length of stay:** NR**Mortality:** None**Uterine preservation, n (%):**Postpartum hysterectomy**G1:** 6 (14)**G2:** 3 (6)p=nsBalloon tamponade**G1:** 9**G2:** 6Brace suture**G1:** 8**G2:** 7**Future fertility:** NR **Breastfeeding:** NR**Psychological impact:** NR**Harms of intervention, n (%):** TACO**G1:** 4 (9)**G2:** 0p= 0.0367TRALI**G1:** 0**G2:** 0**Confounders:** NR **Effect modifiers:** NR |